Abstract: Methods and compositions are provided for diagnosing or inhibiting invasion or metastasis of a cancer in a subject based on MenaINV.

Abstract: The present disclosure provides a method of modulating protein expression from a Mena-ribonucleoprotein (RNP) complex, the method comprising administering to a subject an agent that: (a) inhibits protein expression by inhibiting Mena translation, Mena transcription, or the association of Mena with the Mena-RNP complex, or (b) promotes protein expression by: (i) inhibiting the expression of at least one of HnmpK, PCBP1, or both, or (ii) dissociating at least one of HnmpK, PCBP1, or both, from the Mena-RNP complex in the cell. The present disclosure also provides a method of ameliorating, treating, or preventing at least one symptom of a disease, disorder, or syndrome associated with the overexpression or accumulation of DYRK1A and/or amyloid precursor protein (APP) in cells, as well as a method of ameliorating, treating, or preventing at least one symptom of a disease, disorder, or syndrome associated with the underexpression DYRK1A in cells.

Abstract: Cancer invasion is a hallmark of metastasis. The mesenchymal mode of cancer cell invasion is mediated by elongated membrane protrusions driven by the assembly of branched F-actin networks. Described herein are compositions and methods for assessing and treating a subject having metastatic cancer or at risk of developing metastatic cancer, e.g., metastatic breast cancer, through the determination of Lamellipodin protein or gene expression levels in the subject.

Abstract: Methods and compositions are provided for diagnosing or inhibiting invasion or metastasis of a cancer in a subject based on MenaINV.

Abstract: Methods and compositions are provided for diagnosing or inhibiting invasion or metastasis of a cancer in a subject based on MenaINV.

Abstract: Methods, compounds and kits relating to treating cancer, reducing kinase inhibitor or resistance, and reducing or preventing diminished ectodomain shedding are described.

Abstract: The present invention provides a method for identifying a tumor as likely to metastasize, or likely to have metastasized, comprising obtaining a sample of the tumor and quantitating alternatively spliced mRNA isoforms of a cell motility gene, a cell adhesion gene and/or an actin cytoskeletal remodeling gene in the sample, or any specified genes or the level of RNA binding proteins compared to a predetermined non-metastasizing control.

Abstract: Cancer invasion is a hallmark of metastasis. The mesenchymal mode of cancer cell invasion is mediated by elongated membrane protrusions driven by the assembly of branched F-actin networks. Described herein are compositions and methods for assessing and treating a subject having metastatic cancer or at risk of developing metastatic cancer, e.g., metastatic breast cancer, through the determination of Lamellipodin protein or gene expression levels in the subject.

Abstract: The present disclosure provides methods of treatment and compositions for improving and determining the efficacy of anti-cancer therapies involving tubulin remodeling or protein tyrosine kinase activity by modulating and assaying the presence of certain Mena splicing isoforms.

Abstract: Methods, compounds and kits relating to treating cancer, reducing kinase inhibitor or resistance, and reducing or preventing diminished ectodomain shedding are described.

Abstract: Methods are provided for treating invasion of a tumor or metastasis of a tumor in a subject comprising administering to the subject an agent which inhibits the interaction of Mena with an alpha5 integrin. Assays for identifying agents that inhibit interaction of Mena with an alpha5 integrin are also provided.

Abstract: Methods and compositions are provided for diagnosing or inhibiting invasion or metastasis of a cancer in a subject based on MenaINV.

Abstract: The present invention provides a method for identifying a tumor as likely to metastasize, or likely to have metastasized, comprising obtaining a sample of the tumor and quantitating alternatively spliced mRNA isoforms of a cell motility gene, a cell adhesion gene and/or an actin cytoskeletal remodeling gene in the sample, or any specified genes or the level of RNA binding proteins compared to a predetermined non-metastasizing control.

Abstract: Disclosed are methods for determining the risk of tumor cells undergoing metastasis, for assessing the prognosis of a subject undergoing treatment for a localized tumor, and for determining a course of treatment for a localized tumor comprising detecting the presence of an endothelial cell, a macrophage, and an invasive tumor cell in direct apposition in a tumor sample from a subject.

Abstract: Disclosed are methods for determining the risk of tumor cells undergoing metastasis, for assessing the prognosis of a subject undergoing treatment for a localized tumor, and for determining a course of treatment for a localized tumor comprising detecting the presence of an endothelial cell, a macrophage, and an invasive tumor cell in direct apposition in a tumor sample from a subject.

Abstract: The invention relates to methods for regulating neural growth and regeneration. In particular methods for promoting neural growth are described herein. The methods have a variety of clinical, diagnostic and therapeutic uses.

Abstract: The invention relates to methods for regulating cell motility and related products. In particular methods for promoting and preventing cell migration are described herein. The methods have a variety of clinical, diagnostic and therapeutic uses, e.g., for wound healing, tissue generation, and treatment and prevention of neurodegenerative disease and metastasis.

Abstract: The invention relates to methods for regulating cell motility and related products. In particular methods for promoting and preventing cell migration are described herein. The methods have a variety of clinical, diagnostic and therapeutic uses, e.g., for wound healing, tissue generation, and treatment and prevention of neurodegenerative disease and metastasis.

Abstract: The invention relates to polypeptides which form a protein complex which regulates cytoskeletal reorganization, for example, in connection with T cell activation. The invention also relates to nucleic acids that encode the polypeptides, as well as agents which bind the nucleic acids or the encoded polypeptides. Also disclosed are methods of using such nucleic acids, polypeptides and binding agents to modulate protein complex formation, actin cytoskeletal reorganization and cell activity, as well as drug discovery methods.